

## ABP 215

Cat. No.:	HY-P99476
CAS No.:	1438851-35-4
Target:	VEGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	ABP 215 (Bevacizumab-awwb), a Bevacizumab ( <a href="#">Bevacizumab (HY-P9906)</a> ) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA ( <a href="#">VEGFR</a> ). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research <sup>[1][2]</sup> .
<b>In Vitro</b>	ABP 215 (Bevacizumab-awwb) binds to VEGF-A and prevents the binding of VEGF-A to VEGF receptors on the surface of endothelial cells, inhibiting endothelial cell proliferation and new blood vessel formation, thereby leading to normalization of the tumor vasculature <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Neungseon Seo, et al. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. *MAbs*. 2018 May/June;10(4):678-691.
- [2]. Whitney Rhodes, et al. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. *Future Oncol*. 2021 Dec;17(36):5119-5127.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA